A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer Bioportfolio, 10 Jan 2020 Relevant Topics Cancer Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head